Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $364M (up 71.2% year over year) with net income of −$58M.
Q2 2026 key financials · XBRL
- Revenue
- $364M
- +71.2% YoY · +17.0% QoQ
- Net income
- −$58M
- −37.0% YoY · +38.6% QoQ
- Operating margin
- -15.5%
- EPS (diluted)
- −$1.99
- −4.7% YoY · +38.8% QoQ
Source: XBRL data from the MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q2 2026 10-Q on SEC EDGAR. USD.
MADRIGAL PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $364.3M, up 71% YoY from $212.8M, driven by increased U.S. Rezdiffra demand
- Net loss $57.9M vs $42.3M; operating loss $56.3M vs $47.2M
- Cost of sales $40.0M, up 341%, including $10.4M work-in-process inventory write-down
- Near-term outlook: European launches dependent on reimbursement procedures and regulatory approvals; outcomes data expected in 2027 and 2028
Risk Factors
- Newly adopted CEO Rule 10b5-1 plan, triggered June 5, 2026
- Executive share-sale risk, plan covering maximum 6,706 shares through September 30, 2027
- Financing compliance risk, third amendment with Blue Owl Capital Corporation and LSI Financing LLC dated May 4, 2026
- Equity dilution risk, 2026 Stock Plan and Employee Stock Purchase Plan filed June 17, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MADRIGAL PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.